Science Explorer Back to mapMap
Discussion

SciClone Pharmaceuticals (United States)

Research works
102
▼ 44% vs 2018-21
Citations
4.6k
45.5 per fractional work
Top-10% rate
5.7%
all institutions 10.0%
Open access
23%
world 40%
International
16%
world 18%

Not ranked overall: SciClone Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does SciClone Pharmaceuticals (United States) work in?

In all years, 37% of research at SciClone Pharmaceuticals (United States) is in Health Sciences, 33% in Life Sciences. Its largest fields are Medicine (36%), Biochemistry, Genetics and Molecular Biology (24%), Engineering (21%). It does 2.0× the world's share of Life Sciences.

Health Sciences: 37 fractional works · 36.7% of its workMedicine: 37 fractional works · 36.3% of its workOncology: 13 fractional works · 12.7% of its workRadiology, Nuclear Medicine and Imaging: 6 fractional works · 5.6% of its workEpidemiology: 2 fractional works · 2.3% of its workPulmonary and Respiratory Medicine: 2 fractional works · 2.1% of its workHematology: 2 fractional works · 1.9% of its workEndocrinology, Diabetes and Metabolism: 2 fractional works · 1.7% of its workGenetics: 2 fractional works · 1.5% of its workSurgery: 2 fractional works · 1.5% of its workImmunology and Allergy: 1 fractional works · 1.2% of its workHepatology: 1 fractional works · 0.9% of its workPharmacology: 1 fractional works · 0.8% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 0.6% of its workPathology and Forensic Medicine: 0 fractional works · 0.5% of its workPhysiology: 0 fractional works · 0.5% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.4% of its workGastroenterology: 0 fractional works · 0.4% of its workRheumatology: 0 fractional works · 0.4% of its workInfectious Diseases: 0 fractional works · 0.3% of its workOtorhinolaryngology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.5% of its workNursing: 0 fractional works · 0.3% of its workNutrition and Dietetics: 0 fractional works · 0.3% of its workDentistry: 0 fractional works · 0.1% of its workLife Sciences: 34 fractional works · 33.5% of its workBiochemistry, Genetics and Molecular Biology: 24 fractional works · 23.8% of its workMolecular Biology: 15 fractional works · 14.5% of its workCell Biology: 4 fractional works · 4.1% of its workCancer Research: 3 fractional works · 2.6% of its workBiotechnology: 2 fractional works · 1.7% of its workBiophysics: 1 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.3% of its workImmunology and Microbiology: 8 fractional works · 7.8% of its workImmunology: 8 fractional works · 7.8% of its workNeuroscience: 1 fractional works · 1.0% of its workSensory Systems: 1 fractional works · 0.6% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 0.7% of its workAnimal Science and Zoology: 0 fractional works · 0.3% of its workPlant Science: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.1% of its workPhysical Sciences: 30 fractional works · 29.1% of its workEngineering: 21 fractional works · 21.0% of its workAerospace Engineering: 19 fractional works · 18.7% of its workBiomedical Engineering: 1 fractional works · 1.3% of its workElectrical and Electronic Engineering: 0 fractional works · 0.4% of its workMechanics of Materials: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workComputer Science: 3 fractional works · 3.1% of its workComputer Networks and Communications: 3 fractional works · 2.6% of its workHardware and Architecture: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPhysics and Astronomy: 2 fractional works · 2.2% of its workAstronomy and Astrophysics: 2 fractional works · 1.8% of its workSmaller subfields together: 0 fractional works · 0.4% of its workChemistry: 1 fractional works · 1.1% of its workOrganic Chemistry: 1 fractional works · 0.7% of its workPhysical and Theoretical Chemistry: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workMathematics: 1 fractional works · 1.0% of its workModeling and Simulation: 1 fractional works · 0.6% of its workStatistics and Probability: 0 fractional works · 0.5% of its workMaterials Science: 1 fractional works · 0.7% of its workBiomaterials: 0 fractional works · 0.3% of its workPolymers and Plastics: 0 fractional works · 0.3% of its workEnvironmental Science: 0 fractional works · 0.1% of its workSocial Sciences: 1 fractional works · 0.7% of its workSocial Sciences: 1 fractional works · 0.7% of its workEducation: 0 fractional works · 0.4% of its workTransportation: 0 fractional works · 0.4% of its workALL ITS WORKSciClonePharmaceuticals…102fractional works, all years
Life Sciences33%Physical Sciences29%Health Sciences37%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 16 fields, with their numbers
    1. Medicine3736.3%
    2. Nursing00.3%
    3. Dentistry00.1%
    1. Biochemistry, Genetics and Molecular Biology2423.8%
    2. Immunology and Microbiology87.8%
    3. Neuroscience11.0%
    4. Agricultural and Biological Sciences10.7%
    5. Pharmacology, Toxicology and Pharmaceutics00.1%
    1. Engineering2121.0%
    2. Computer Science33.1%
    3. Physics and Astronomy22.2%
    4. Chemistry11.1%
    5. Mathematics11.0%
    6. Materials Science10.7%
    7. Environmental Science00.1%
    1. Social Sciences10.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.11× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 12.83× its world share, 1 worksImmunology and Micro…Neuroscience: 0.99× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 3.43× its world share, 0 worksPharmacology, Toxico…Computer Science: 1.14× its world share, 1 worksComputer ScienceEngineering: 1.29× its world share, 1 worksEngineeringMedicine: 2.61× its world share, 3 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 12.8×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Immunology and Microbiology12.83×1 works
  2. Pharmacology, Toxicology and Pharmaceutics3.43×0 works
  3. Medicine2.61×3 works
  4. Engineering1.29×1 works
  5. Computer Science1.14×1 works
  6. Biochemistry, Genetics and Molecular Biology1.11×0 works
  7. Neuroscience0.99×0 works

Who are the top researchers at SciClone Pharmaceuticals (United States)?

Ranked on the quality score, Larry Witte, Xenia Jimenez and Cynthia W. Tuthill lead among researchers whose main affiliation is SciClone Pharmaceuticals (United States).

  1. 1 Larry Witte United States · #156,540 worldwide 14k citations · 95 works
  2. 2 Xenia Jimenez United States · #782,431 worldwide 2.4k citations · 37 works
  3. 3 Cynthia W. Tuthill United States · #5,035,772 worldwide 647 citations · 38 works
  4. 4 Andrew Santangelo United States · #6,604,807 worldwide 144 citations · 83 works
All ranked researchers at SciClone Pharmaceuticals (United States)

What are the most cited papers from SciClone Pharmaceuticals (United States)?

The most cited paper from SciClone Pharmaceuticals (United States) is "mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt" (Kathryn E O'Reilly, F. Rojo, Qing‐Bai She et al., 2006), with 2,599 citations. Next come "Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth" (1,864) and "Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors" (1,195).

Most cited papers
#PaperReleasedCitations
1 mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Kathryn E O'Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research Open access Feb 2006 2,599
2 Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth David C. Lyden, Koichi Hattori, Sérgio Dias et al. · Nature Medicine Nov 2001 1,864
3 Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors Ricky T. Tong, Yves Boucher, Sergey V. Kozin et al. · Cancer Research Open access Jun 2004 1,195
4 Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration Bert Oosthuyse et al. · Nature Genetics Jun 2001 1,016
5 Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 Monica Autiero et al. · Nature Medicine 8 Jun 2003 774
All 62 most cited papers, with filters and sorting

Which keywords describe research at SciClone Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Thermal Analysis, CubeSat, small satellite, Inflammation, Glycosylation, Monoclonal Antibodies, Cancer and Therapeutic Antibodies.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Inflammation10▲ 4.3×25 topics
  2. Thermal Analysis9▲ 58×2 topics
  3. CubeSat8▲ 333×1 topic
  4. small satellite8▲ 333×1 topic
  5. Cancer8▲ 5.8×18 topics
  6. Glycosylation7▲ 33×3 topics
  7. Monoclonal Antibodies7▲ 49×3 topics
  8. LEO Satellite Constellation7▲ 341×1 topic
  9. Satellite Communications7▲ 341×1 topic
  10. Therapeutic Antibodies7▲ 54×2 topics
  11. Angiogenesis6▲ 14×10 topics
  12. Antibody Engineering5▲ 53×1 topic
  13. Fc Receptors5▲ 53×1 topic
  14. VEGF5▲ 150×1 topic
  15. endothelial progenitor cells5▲ 150×1 topic
  16. Chemotherapy5▲ 6.5×10 topics
  17. Tumor Microenvironment4▲ 9.9×6 topics
  18. Immunity4▲ 10×5 topics
  19. Metabolism4▲ 5.3×4 topics
  20. Neurotoxicity3▲ 17×2 topics
  21. Chemotherapy-Induced Peripheral Neuropathy3▲ 55×1 topic
  22. Innate Immunity3▲ 7.8×4 topics
  23. Taxanes3▲ 55×1 topic
  24. Toll-like Receptors3▲ 17×3 topics
  25. Cancer Therapy3▲ 4.2×9 topics
  26. Cell Signaling3▲ 7.9×6 topics
  27. Cancer Immunotherapy2▲ 18×2 topics
  28. Cell Migration2▲ 28×3 topics
  29. Biopharmaceuticals2▲ 33×3 topics
  30. Monoclonal Antibody2▲ 33×2 topics
  31. Extracellular Matrix2▲ 9.1×3 topics
  32. On-Orbit Servicing2▲ 107×1 topic
  33. Space Debris2▲ 107×1 topic
  34. Targeted Therapy2▲ 9.8×4 topics
  35. Recombinant Proteins2▲ 39×2 topics
  36. Trastuzumab2▲ 47×2 topics
  37. Distributed Systems2▲ 8.0×2 topics
  38. Tumor Regression2▲ 22×2 topics
  39. Cancer Progression2▲ 8.3×3 topics
  40. Stability2▲ 9.9×2 topics

Which research topics does SciClone Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Cancer Treatment and Pharmacology, Spacecraft Design and Technology, Distributed systems and fault tolerance and Space Satellite Systems and Control.

  1. 1 Cancer Treatment and Pharmacology Oncology 1 works
  2. 2 Spacecraft Design and Technology Aerospace Engineering 0 works
  3. 3 Distributed systems and fault tolerance Computer Networks and Communications 0 works
  4. 4 Space Satellite Systems and Control Aerospace Engineering 0 works
  5. 5 Pediatric Hepatobiliary Diseases and Treatments Surgery 0 works
  6. 6 Immune responses and vaccinations Immunology 0 works
  7. 7 Cancer Immunotherapy and Biomarkers Oncology 0 works
  8. 8 Immune cells in cancer Immunology 0 works
  9. 9 Drug Transport and Resistance Mechanisms Oncology 0 works
  10. 10 Antibiotic Resistance in Bacteria Molecular Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available22.9%not open77.1%

World: 40% of research is openly available.

with international co-authors16.2%domestic only83.8%

World: 18% is written across borders.

How has SciClone Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 44% lower than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is SciClone Pharmaceuticals (United States) as a percentage of every work published that year, 0.000019% in 2024.

still counting0.00020%0.00040%0.00060%SciClone Pharmaceuticals (United States)0.000042% in 2025200020102020

Fractional works of SciClone Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Foster City

All research institutions in Foster City

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about SciClone Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.